Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses.
Cellular immune response plays an important role in antiviral immunity. In our previous study, immunization of mice with severe acute respiratory syndrome coronavirus (SARS CoV) spike (S) DNA vaccine could induce both humoral and cellular immunity in response to a pool of entire overlapping S peptides. Identification of functional dominant epitopes in SARS CoV S protein for T cells is crucial for further understanding of cellular immune responses elicited by SARS CoV S DNA vaccine. In present study, mice were immunized with SARS CoV S DNA vaccine. Subsequently, a pool of 17-19 mers overlapped SARS CoV S peptides, which served as immunogens, were scanned to identify the specific epitopes for T cells. Two H-2(d) restricted CD4(+) T epitopes, N60 (S435-444) and P152 (S1111-1127), and two H-2(d) restricted CD8(+) T cell epitopes, N50 (S365-374) and P141 (S1031-1047) were identified by three different methods, enzyme-linked immunosorbent assay (ELISA), enzyme linked immunospot assay (ELISPOT) and fluorescence activated cell sorter (FACS). The dominant CD4(+) T cell epitope (N60) and CD8(+) T cell epitope (N50) located in the receptor-binding domain (RBD) of SARS CoV S protein, which mediated virus combining and fusing to susceptible cells. Importantly, our novel finding is that mice primed with SARS S DNA vaccine and boosted with T cell epitopes (N50 and N60) could promote antigen specific CD4(+) and CD8(+) T cell immune responses. Our study provides valuable information for the design of vaccine for SARS study.
Huang
Jun
J
Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Cao
Yingnan
Y
Du
Jiali
J
Bu
Xianzhang
X
Ma
Rui
R
Wu
Changyou
C
D000595:Amino Acid Sequence; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D005260:Female; D007114:Immunization; D007117:Immunization, Secondary; D016056:Immunodominant Epitopes; D007156:Immunologic Memory; D008562:Membrane Glycoproteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D045473:Severe acute respiratory syndrome-related coronavirus / Q000276:immunology*; D045169:Severe Acute Respiratory Syndrome / Q000276:immunology / Q000517:prevention & control; D064370:Spike Glycoprotein, Coronavirus; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology; D014759:Viral Envelope Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology
D018984:Epitopes, T-Lymphocyte; D016056:Immunodominant Epitopes; D008562:Membrane Glycoproteins; D010455:Peptides; D064370:Spike Glycoprotein, Coronavirus; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus
Virology. 1999 Feb 1;254(1):50-60
9927573
Emerg Infect Dis. 2005 Jul;11(7):1016-20
16022774
Lancet. 2004 Jun 26;363(9427):2122-7
15220033
J Exp Med. 2003 Dec 15;198(12):1797-806
14662907
J Mol Recognit. 1993 Jun;6(2):81-94
7508238
J Infect Dis. 2004 Sep 15;190(6):1119-26
15319862
J Virol. 2004 Jul;78(13):6938-45
15194770
Curr Opin Immunol. 2003 Aug;15(4):461-70
12900280
Trends Immunol. 2004 Feb;25(2):98-104
15102369
J Virol. 2005 Nov;79(22):13915-23
16254327
J Immunol. 2006 Aug 15;177(4):2138-45
16887973
Microbes Infect. 2005 Mar;7(3):427-36
15784184
Science. 2003 May 30;300(5624):1394-9
12730500
Virology. 2005 Apr 25;335(1):34-45
15823604
Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52
15530413
Lancet. 2003 Apr 19;361(9366):1319-25
12711465
J Virol. 2004 Jun;78(11):5612-8
15140958
J Exp Med. 2005 Jul 4;202(1):123-33
15983064
Vaccine. 2006 Jun 29;24(26):5498-508
16725238
Vaccine. 2005 Aug 15;23(35):4385-91
16005746
J Virol. 2006 Feb;80(4):2034-44
16439559
Clin Immunol. 2006 Aug;120(2):171-8
16781892
Blood. 2004 Jul 1;104(1):200-6
15016646
J Biol Chem. 2004 Jan 30;279(5):3197-201
14670965
Microbes Infect. 2006 Aug;8(9-10):2424-31
16844400
Nature. 2003 Nov 27;426(6965):450-4
14647384
J Comb Chem. 2005 Sep-Oct;7(5):648-56
16153058
Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53
15496474
N Engl J Med. 2003 May 15;348(20):1967-76
12690091
J Virol. 2004 Jun;78(12):6134-42
15163706
Clin Microbiol Infect. 2004 Jul;10(7):676-8
15214887
J Virol. 2004 Nov;78(22):12672-6
15507655
Nat Immunol. 2003 Dec;4(12):1191-8
14625547
Virology. 2006 Aug 1;351(2):466-75
16690096
Nature. 2003 Feb 20;421(6925):852-6
12594515
Nat Med. 2005 Aug;11(8):875-9
16007097
Virology. 2007 Mar 15;359(2):264-74
17055022
Nature. 2004 Apr 1;428(6982):561-4
15024391
Vaccine. 2006 Jun 5;24(23):4905-13
16621188
J Immunol. 2005 Oct 1;175(7):4686-96
16177116